A genetic test for immunosuppressant dose selection?

被引：15

作者：

Thummel, KE ^{[1
]}

机构：

[1] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA

来源：

PHARMACOGENETICS | 2004年 / 14卷 / 03期

关键词：

D O I：

10.1097/00008571-200403000-00001

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：145 / 146

页数：2

共 13 条

[1]

AOYAMA T, 1989, J BIOL CHEM, V264, P10388

[2] Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions [J].

Bader, A ;

Hansen, T ;

Kirchner, G ;

Allmeling, C ;

Haverich, A ;

Borlak, JT .

BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (02) :331-342

[3] Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women [J].

Floyd, MD ;

Gervasini, G ;

Masica, AL ;

Mayo, G ;

George, AL ;

Bhat, K ;

Kim, RB ;

Wilkinson, GR .

PHARMACOGENETICS, 2003, 13 (10) :595-606

[4] Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies [J].

Goh, BC ;

Lee, SC ;

Wang, LZ ;

Fan, L ;

Guo, JY ;

Lamba, J ;

Schuetz, E ;

Lim, R ;

Lim, HL ;

Ong, AB ;

Lee, HS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3683-3690

[5] The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients [J].

Haufroid, V ;

Mourad, M ;

Van Kerckhove, V ;

Wawrzyniak, J ;

De Meyer, M ;

Eddour, DC ;

Malaise, J ;

Lison, D ;

Squifflet, JP ;

Wallemacq, P .

PHARMACOGENETICS, 2004, 14 (03) :147-154

[6] Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus [J].

Hesselink, DA ;

van Schaik, RHN ;

van der Heiden, IP ;

van der Werf, M ;

Gregoor, PJHS ;

Lindemans, J ;

Weimar, W ;

van Gelder, T .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (03) :245-254

[7] The genetic determinants of the CYP3A5 polymorphism [J].

Hustert, E ;

Haberl, M ;

Burk, O ;

Wolbold, R ;

He, YQ ;

Klein, K ;

Nuessler, AC ;

Neuhaus, P ;

Klattig, J ;

Eiselt, R ;

Koch, I ;

Zibat, A ;

Brockmöller, J ;

Halpert, JR ;

Zanger, UM ;

Wojnowski, L .

PHARMACOGENETICS, 2001, 11 (09) :773-779

[8] Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].

Kuehl, P ;

Zhang, J ;

Lin, Y ;

Lamba, J ;

Assem, M ;

Schuetz, J ;

Watkins, PB ;

Daly, A ;

Wrighton, SA ;

Hall, SD ;

Maurel, P ;

Relling, M ;

Brimer, C ;

Yasuda, K ;

Venkataramanan, R ;

Strom, S ;

Thummel, K ;

Boguski, MS ;

Schuetz, E .

NATURE GENETICS, 2001, 27 (04) :383-391

[9] Genetic contribution to variable human CYP3A-mediated metabolism [J].

Lamba, JK ;

Lin, YS ;

Schuetz, EG ;

Thummel, KE .

ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (10) :1271-1294

[10] Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism [J].

Lin, YS ;

Dowling, ALS ;

Quigley, SD ;

Farin, FM ;

Zhang, J ;

Lamba, J ;

Schuetz, EG ;

Thummel, KE .

MOLECULAR PHARMACOLOGY, 2002, 62 (01) :162-172

← 1 2 →